Razoxane, (R)-

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 598748

CAS#: 24613-06-7

Description: Razoxane, (R)- exhibits antiangiogenic effects.

Chemical Structure

img
Razoxane, (R)-
CAS# 24613-06-7
Instruction

Theoretical Analysis

MedKoo Cat#: 598748
Name: Razoxane, (R)-
CAS#: 24613-06-7
Chemical Formula: C11H16N4O4
Exact Mass: 268.12
Molecular Weight: 268.270
Elemental Analysis: C, 49.25; H, 6.01; N, 20.88; O, 23.85

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Razoxane, (R)-; ICRF-186; ICRF 186; ICRF186; NSC-169779; NSC 169779; NSC169779; Levrazoxane;

IUPAC/Chemical Name: (R)-4,4'-(propane-1,2-diyl)bis(piperazine-2,6-dione)

InChi Key: BMKDZUISNHGIBY-SSDOTTSWSA-N

InChi Code: InChI=1S/C11H16N4O4/c1-7(15-5-10(18)13-11(19)6-15)2-14-3-8(16)12-9(17)4-14/h7H,2-6H2,1H3,(H,12,16,17)(H,13,18,19)/t7-/m1/s1

SMILES Code: C[C@@H](N(C1)CC(NC1=O)=O)CN(C2)CC(NC2=O)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 268.27 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Limat S, Daguindau E, Cahn JY, Nerich V, Brion A, Perrin S, Woronoff-Lemsi MC, Deconinck E. Incidence and risk-factors of CHOP/R-CHOP-related cardiotoxicity in patients with aggressive non-Hodgkin's lymphoma. J Clin Pharm Ther. 2014 Apr;39(2):168-74. doi: 10.1111/jcpt.12124. Epub 2014 Jan 3. PubMed PMID: 24384030.

2: Chow EJ, Asselin BL, Schwartz CL, Doody DR, Leisenring WM, Aggarwal S, Baker KS, Bhatia S, Constine LS, Freyer DR, Lipshultz SE, Armenian SH. Late Mortality After Dexrazoxane Treatment: A Report From the Children's Oncology Group. J Clin Oncol. 2015 Aug 20;33(24):2639-45. doi: 10.1200/JCO.2014.59.4473. Epub 2015 May 26. PubMed PMID: 26014292; PubMed Central PMCID: PMC4534526.

3: Anderson H, Yap JT, Wells P, Miller MP, Propper D, Price P, Harris AL. Measurement of renal tumour and normal tissue perfusion using positron emission tomography in a phase II clinical trial of razoxane. Br J Cancer. 2003 Jul 21;89(2):262-7. PubMed PMID: 12865914; PubMed Central PMCID: PMC2394254.

4: Klenner T, Wingen F, Keppler B, Valenzuela-Paz P, Amelung F, Schmähl D. Therapeutic efficacy of two different cytostatic-linked phosphonates in combination with razoxane in the transplantable osteosarcoma of the rat. Clin Exp Metastasis. 1990 Jul-Aug;8(4):345-59. PubMed PMID: 2350920.

5: Sun F, Qi X, Geng C, Li X. Dexrazoxane protects breast cancer patients with diabetes from chemotherapy-induced cardiotoxicity. Am J Med Sci. 2015 May;349(5):406-12. doi: 10.1097/MAJ.0000000000000432. PubMed PMID: 25723884.

6: Neckář J, Boudíková A, Mandíková P, Stěrba M, Popelová O, Mikšík I, Dabrowská L, Mráz J, Geršl V, Kolář F. Protective effects of dexrazoxane against acute ischaemia/reperfusion injury of rat hearts. Can J Physiol Pharmacol. 2012 Sep;90(9):1303-10. doi: 10.1139/y2012-096. Epub 2012 Aug 22. PubMed PMID: 22913659.

7: Kamat P, Vandenberghe S, Christen S, Bongoni AK, Meier B, Rieben R, Khattab AA. Dexrazoxane Shows No Protective Effect in the Acute Phase of Reperfusion during Myocardial Infarction in Pigs. PLoS One. 2016 Dec 21;11(12):e0168541. doi: 10.1371/journal.pone.0168541. eCollection 2016. PubMed PMID: 28002439; PubMed Central PMCID: PMC5176296.

8: Hasinoff BB. Enzymatic ring-opening reactions of the chiral cardioprotective agent (+) (S)-ICRF-187 and its (-) (R)-enantiomer ICRF-186 by dihydropyrimidine amidohydrolase. Drug Metab Dispos. 1993 Sep-Oct;21(5):883-8. PubMed PMID: 7902252.

9: Baldwin JR, Lewis RC, Phillips BA, Overmyer SK, Hatfield NZ, Narang PK. Dose-independent pharmacokinetics of the cardioprotective agent dexrazoxane in dogs. Biopharm Drug Dispos. 1996 Aug;17(6):541-50. PubMed PMID: 8866044.

10: Ishida R, Miki T, Narita T, Yui R, Sato M, Utsumi KR, Tanabe K, Andoh T. Inhibition of intracellular topoisomerase II by antitumor bis(2,6-dioxopiperazine) derivatives: mode of cell growth inhibition distinct from that of cleavable complex-forming type inhibitors. Cancer Res. 1991 Sep 15;51(18):4909-16. PubMed PMID: 1654205.

11: Vigevani A, Zampieri M, Pellizzato R. Thermal behaviour and binary phase diagram of (S)-(+)-4,4'-(1-methyl-1,2-ethandiyl)-bis-(2,6-piperazinedione) (dexrazoxane), a cardioprotective agent, and of its (R)-(-)-enantiomer. J Pharm Biomed Anal. 1992 Jan;10(1):31-6. PubMed PMID: 1391080.

12: Sargent JM, Williamson CJ, Yardley C, Taylor CG, Hellmann K. Dexrazoxane significantly impairs the induction of doxorubicin resistance in the human leukaemia line, K562. Br J Cancer. 2001 Apr 6;84(7):959-64. PubMed PMID: 11286477; PubMed Central PMCID: PMC2363849.

13: Rhomberg W, Gruber-Mösenbacher U, Eiter H, Fritzsche H, Breitfellner G. [Prognosis and epidemiology of malignant hemangioendotheliomas of the thyroid gland]. Schweiz Med Wochenschr. 1993 Sep 4;123(35):1640-4. German. PubMed PMID: 8211014.

14: Thirupathi C, Nagesh Kumar K, Srinivasu G, Lakshmi Narayana C, Parameswara Murthy C. Development and Validation of Stereo Selective Method for the Separation of Razoxane Enantiomers in Hydrophilic Interaction Chromatography. J Chromatogr Sci. 2018 Feb 1;56(2):147-153. doi: 10.1093/chromsci/bmx094. PubMed PMID: 29140426.

15: Xue Y, Guo Y, Xie X. Translocation t(7;11)(P15;P15) in a patient with therapy-related acute myeloid leukemia following bimolane and ICRF-154 treatment for psoriasis. Leuk Res. 1997 Feb;21(2):107-9. PubMed PMID: 9112426.

16: Hasinoff BB, Kuschak TI, Yalowich JC, Creighton AM. A QSAR study comparing the cytotoxicity and DNA topoisomerase II inhibitory effects of bisdioxopiperazine analogs of ICRF-187 (dexrazoxane). Biochem Pharmacol. 1995 Sep 28;50(7):953-8. PubMed PMID: 7575679.

17: Xue Y, Lu D, Guo Y, Lin B. Specific chromosomal translocations and therapy-related leukemia induced by bimolane therapy for psoriasis. Leuk Res. 1992 Nov;16(11):1113-23. PubMed PMID: 1434747.

18: Potácová A, Adamcová M, Cajnáková H, Hrbatová L, Sterba M, Popelová O, Simůnek T, Ponka P, Gersl V. Evaluation of ECG time intervals in a rabbit model of anthracycline-induced cardiomyopathy: a useful tool for assessment of cardioprotective agents. Physiol Res. 2007;56(2):251-4. PubMed PMID: 17504005.

19: Loyevsky M, Sacci JB Jr, Boehme P, Weglicki W, John C, Gordeuk VR. Plasmodium falciparum and Plasmodium yoelii: effect of the iron chelation prodrug dexrazoxane on in vitro cultures. Exp Parasitol. 1999 Feb;91(2):105-14. PubMed PMID: 9990337.

20: Diop NK, Vitellaro LK, Arnold P, Shang M, Marusak RA. Iron complexes of the cardioprotective agent dexrazoxane (ICRF-187) and its desmethyl derivative, ICRF-154: solid state structure, solution thermodynamics, and DNA cleavage activity. J Inorg Biochem. 2000 Feb;78(3):209-16. PubMed PMID: 10805177.